UNH — Q1 2026 Earnings Dashboard

Q1 2026 Earnings — Reported April 21, 2026 · Before Market Open · Stock +8% on Results

Revenue $111.7B (+2%) · Adj. EPS $7.23 vs $6.57 est. · MCR Improves to 83.9% · Guidance Raised

UnitedHealth Group delivered a significant beat on adjusted EPS — $7.23 vs $6.57 estimated (+10.0%) — as actions taken over prior quarters stabilized the business. Revenue of $111.7B (+2% YoY) topped the $109.6B consensus. The medical care ratio improved 90bps to 83.9%, reflecting better pricing and reserve development. Operating cash flow was $8.9B (1.4x net income). Full-year adjusted EPS guidance raised to >$18.25 from >$17.75. Stock surged ~8% on the day. DOJ investigation and Medicare Advantage membership decline remain key overhangs.

Beats

Adj. EPSEst. $6.57$7.23 (+10.0%)

RevenueEst. $109.57B$111.72B (+2.0%)

UHC RevenueStreet est.$86.3B (topped est.)

Optum RevenueStreet est.$63.7B (topped est.)

Medical Care Ratio~84.5% est.83.9% (−90bps YoY)

FY2026 Adj. EPS GuidancePrior >$17.75Raised to >$18.25

Concerns

Total Revenue growthPrior year growth ~12%Only +2% YoY

UHC Medical Membership—49.1M · −2.3–2.8M FY26 expected

Medicare Advantage attrition—−1.1M expected FY2026

Medicaid margins—Negative · no recovery until 2027

Optum Health Op. Earnings—−15% YoY · elevated medical costs

DOJ investigation—Criminal + civil probe ongoing

Select Consolidated Results — Three Months Ended March 31, 2026

Total Revenues$111,721M$109,577M+2%

UnitedHealthcare Revenue$86,265M$84,596M+2%

Optum Revenue (total)$63,749M$63,574MFlat

Optum Health$22,928M—+growth

Optum Insight$5,100M$5,000M+2%

Optum Rx$35,700M$35,000M+2%

Earnings from Operations$9,024M—Strong

Net Margin5.6%5.7%−10bps

Medical Care Ratio (MCR)83.9%84.8%−90bps

Operating Cost Ratio13.8%—Investments

GAAP Net Income$6,481M—Stable

GAAP Diluted EPS$6.90$6.91Flat YoY

Adj. EPS (non-GAAP)$7.23—Beat +10%

Operating Cash Flow$8,912M—1.4x net income

Debt-to-Capital Ratio42.9%—Manageable

UnitedHealthcare — $86.3B (+2%)

Operating earnings$5.7B · margin 6.6% (+40bps)

Medical membership49.1M · declining

Medicare Advantage attrition~−1.1M expected FY2026

Medicaid marginsNegative · 2027 recovery est.

Employer-sponsored plansGrowth offsetting govt. declines

Digital engagement~50% members · 73M Q1 visits

Avery AI chatbotExpanding to 20M+ members

Optum — $63.7B (Flat YoY)

Optum Health op. earnings−15% YoY · elevated medical costs

Optum Health margin5.7% Q1 · target 6–8% LT

Optum Insight revenue$5.1B (+2% YoY)

Optum Insight margin23.2% · strong

Optum Rx revenue$35.7B (+2%) · 383M adj. scripts

Optum Rx margin3.8%

New OptumRx clients (Q1)800+ new clients onboarded

"We are continuing to help simplify and modernize health care for the people and care providers we serve, bringing greater value, affordability, transparency and connectivity. Our first quarter 2026 results reflect performance supported by actions taken over the last several quarters. Looking ahead, we aim to successfully execute our commercial plans and tightly manage costs to help fund investments to accelerate growth."

Stephen Hemsley, CEO · Q1 2026 Earnings Call, April 21, 2026

Positives

▲

Adjusted EPS of $7.23 beat $6.57 consensus by 10.0% — the largest positive earnings surprise from UnitedHealth in several quarters. The beat was driven by improved MCR at 83.9% (−90bps YoY) reflecting pricing actions, favorable prior period reserve development, and affordability initiatives bearing fruit.

▲

FY2026 adjusted EPS guidance raised to >$18.25 from >$17.75 — a $0.50 per share increase confirmed only one quarter in. This guidance raise signals management's growing confidence that the Medicare Advantage repricing and Optum margin recovery are tracking ahead of plan.

▲

Operating cash flow of $8.9B (1.4x net income) demonstrates strong earnings quality — cash is real and near the top of the healthcare sector. This cash generation funds the ≥$2B share repurchase commitment by end of Q2 2026 while maintaining balance sheet discipline.

▲

UnitedHealthcare operating margin expanded 40bps to 6.6% — Optum Health margin recovered to 5.7% toward the 6–8% long-term target. Goldman Sachs added UNH to its Conviction Buy list on May 1 citing a bottoming Medicare Advantage underwriting cycle as a key catalyst.

▲

Digital and AI transformation is measurable: 73M digital member visits in Q1, 50% of members using digital tools (up 42% in two years), 800+ new OptumRx clients onboarded with call center volume reduced 25% via AI self-service. ~$1B in AI-enabled cost reductions targeted for FY2026.

Concerns

▼

DOJ criminal and civil investigation into Medicare Advantage billing practices — specifically whether the company inflated diagnoses to trigger higher government reimbursements — remains the primary systemic risk. No resolution timeline has been announced. A forced divestiture of Optum would fundamentally destroy the integrated business model.

▼

UHC medical membership at 49.1M and declining — the company expects 2.3–2.8M total membership attrition in FY2026 due to Medicare Advantage repricing and Medicaid redeterminations. Membership is the revenue engine; sustained attrition limits top-line growth regardless of margin improvement.

▼

Medicaid segment margins are negative and management explicitly guided no recovery until 2027 at the earliest — stating ongoing membership attrition and insufficient state funding will persist through all of 2026. This is a structural drag on Optum Health earnings.

▼

Optum Health operating earnings declined 15% YoY — driven by elevated medical cost trends and Medicare funding pressure in its value-based care physician business. The recovery to the 6–8% long-term margin target is dependent on Medicaid funding resolution and Medicare rate normalization.

▼

Total revenue growth of only +2% YoY represents a dramatic deceleration from +12% in FY2025 — driven by Medicare Advantage pricing resets and membership attrition. The company's FY2026 revenue guidance of >$439B implies continued modest top-line growth while earnings recover through cost management.

Wall Street Ratings — Post April 21, 2026

Firm	Rating	Price Target	Action	Note
Goldman Sachs	Conviction Buy	—	Added May 1	Bottoming Medicare Advantage underwriting cycle as key catalyst
Evercore ISI	Outperform	$400	Raised post Q1	Q1 beat + guidance raise confirms recovery is underway
Bullish consensus	Buy / Overweight	$380–420	Multiple raises	MCR improvement + adj. EPS raise vs depressed expectations
Cautious view	Hold / Neutral	$300–340	DOJ risk	DOJ probe + structural Medicare funding headwinds
Stock vs. March 2026 low	+47%	~$382	Recovery from $283	52-week high ~$630 · still −47% from peak
Stock on Q1 day	+8%	~$382	+8% AM trading	EPS beat + guidance raise the primary catalysts

Earnings Verdict

Recovery Underway — DOJ Cloud Remains the Defining Risk

UnitedHealth Group's Q1 2026 marked the clearest evidence yet that the multi-quarter operational reset is producing results. A 10% adjusted EPS beat, improved MCR at 83.9%, raised FY2026 guidance, and strong $8.9B operating cash flow collectively confirmed that pricing actions and cost discipline are working ahead of internal expectations. The stock's 8% single-day surge and +47% recovery from the March 2026 low at $283 reflects a market repricing from distressed expectations to cautious optimism. The fundamental concerns cannot be dismissed: total revenue growth of only +2% YoY, Medicare Advantage and Medicaid membership attrition continuing through 2026, Optum Health earnings down 15% YoY, and the unresolved DOJ criminal and civil investigation into billing practices that remains a binary, potentially business-model-altering risk. Goldman Sachs' Conviction Buy addition and Evercore's $400 PT raise post-Q1 signal growing Wall Street conviction that the MA underwriting cycle is bottoming. The path to $18.25+ FY2026 EPS and recovery toward the prior $630 peak requires sustained MCR improvement and DOJ resolution. Next earnings July 2026.

Adj. EPS Beat

+10.0%

MCR

83.9% −90bps

FY Guide Raised

>$18.25

Op. Cash Flow

$8.9B

Key Risk

DOJ Investigation

Next Earnings

Jul 2026